|
Characteristic (n = 67)
|
Mean (SD)
|
Mean rank
|
p-value
|
|---|
|
Nationality
|
|
Lebanese (n = 60)
|
41.11 (32.24)
|
33.40
|
0.452
|
|
Non-Lebanese (n = 7)
|
50.79 (31.98)
|
39.14
|
|
Marital status
|
|
Non married (n = 9)
|
35.80 (32.29)
|
30.22
|
0.524
|
|
Married (n = 58)
|
43.10 (32.24)
|
34.59
|
|
Education level
|
|
Primary (n = 9)
|
28.40 (24.29)
|
24.89
|
0.097
|
|
Secondary (n = 41)
|
48.51 (31.70)
|
36.76
|
|
University (n = 15)
|
34.07 (34.24)
|
27.60
|
|
Socioeconomic level
|
|
Low (n = 3)
|
18.52 (16.97)
|
18.83
|
0.177
|
|
Middle (n = 58)
|
44.44 (32.58)
|
35.07
|
|
High (n = 5)
|
24.44 (26.53)
|
24.10
|
|
Professional activity
|
|
Yes (n = 22)
|
48.48 (34.55)
|
37.55
|
0.289
|
|
No (n = 45)
|
39.01 (30.76)
|
32.27
|
|
Alcohol
|
|
No (n = 59)
|
43.13 (31.36)
|
34.64
|
0.460
|
|
Yes (n = 8)
|
34.72 (38.69)
|
29.31
|
|
Tobacco
|
|
No (n = 45)
|
45.43 (31.14)
|
36.01
|
0.353
|
|
Yes (n = 19)
|
37.42 (33.58)
|
31.11
|
|
Previous smoker (n = 3)
|
22.22 (38.49)
|
22.17
|
|
Allergy
|
|
No (n = 62)
|
39.96 (31.46)
|
32.77
|
0.065
|
|
Yes (n = 5)
|
68.89 (30.83)
|
49.20
|
|
Dyslipidemia
|
|
No (n = 56)
|
40.08 (31.90)
|
32.85
|
0.266
|
|
Yes (n = 11)
|
52.53 (32.62)
|
39.86
|
|
Diabetes
|
|
No (n = 62)
|
42.11 (33.19)
|
33.89
|
0.865
|
|
Yes (n = 5)
|
42.22 (14.49)
|
35.40
|
|
Hypertension
|
|
No (n = 50)
|
44.00 (32.53)
|
35.20
|
0.379
|
|
Yes (n = 17)
|
36.60 (31.12)
|
30.47
|
|
Oral antidiabetics
|
|
No (n = 62)
|
42.11 (33.19)
|
33.89
|
0.865
|
|
Yes (n = 5)
|
42.22 (14.49)
|
35.40
|
|
Antihypertensive drugs
|
|
No (n = 52)
|
42.52 (32.76)
|
34.31
|
0.806
|
|
Yes (n = 15)
|
40.74 (30.77)
|
32.93
|
|
Dyslipidemia treatment
|
|
No (n = 57)
|
39.38 (32.06)
|
32.40
|
0.103
|
|
Yes (n = 10)
|
57.78 (39.07)
|
43.10
|
|
Antidepressant treatment
|
|
No (n = 59)
|
41.05 (31.17)
|
33.47
|
0.542
|
|
Yes (n = 8)
|
50.00 (39.84)
|
37.88
|
|
Antipsychotic treatment
|
|
No (n = 63)
|
40.56 (30.80)
|
33.21
|
0.178
|
|
Yes (n = 4)
|
66.67 (47.14)
|
46.50
|
|
Neurogenic pain treatment
|
|
No (n = 64)
|
40.45 (31.14)
|
33.16
|
0.095
|
|
Yes (n = 3)
|
77.78 (38.49)
|
52.00
|
|
Notable treatmenta
|
|
No (n = 60)
|
40.86 (32.52)
|
32.26
|
0.122
|
|
Yes (n = 7)
|
58.73 (21.96)
|
43.93
|
|
Metastasis
|
|
No (n = 60)
|
38.70 (31.39)
|
31.93
|
0.010
|
|
Yesb (n = 7)
|
71.43 (23.00)
|
51.71
|
|
Metastasis type
| | |
0.021
|
|
No (n = 60)
|
38.70 (31.39)
|
31.93
|
Ref
|
|
Bone (n = 5)
|
80.00 (18.26)
|
56.30
|
0.011
|
|
Pulmonary (n = 2)
|
50.00 (23.57)
|
40.25
|
0.945
|
|
Chemotherapy type
| | |
0.005
|
|
Palliative (n = 7)
|
71.43 (23.00)
|
50.71
|
Ref
|
|
Adjuvant (n = 44)
|
34.63 (31.16)
|
28.47
|
0.010
|
|
Neoadjuvant (n = 16)
|
52.08 (28.60)
|
39.50
|
0.332
|
|
Cyclophosphamide treatmentc
|
|
No (n = 36)
|
49.38 (31.02)
|
38.13
|
0.057
|
|
Yes (n = 31)
|
33.69 (31.75)
|
29.21
|
|
Capecitabine treatmentc
|
|
No (n = 62)
|
39.07 (31.09)
|
32.20
|
0.007
|
|
Yes (n = 5)
|
80.00 (18.26)
|
56.30
|
- Numbers in bold are significant results (p < 0.05)
- aThese treatments include benzodiazepines (alprazolam, bromazepam, clonazepam, lorazepam), opioids (tramadol and codeine) and zolpidem
- bPatients with metastasis were not considered as having a relapsed breast cancer (thus not excluded) because they had a primary diagnosis of metastatic breast cancer
- cOther treatment types did not give significant results
